Your browser doesn't support javascript.
loading
Evolving Industry Partnerships and Investments in Cell and Gene Therapies.
Smith, Devyn M; Culme-Seymour, Emily J; Mason, Chris.
Affiliation
  • Smith DM; Sigilon Therapeutics, 100 Binney Street, Suite 600, Cambridge, MA 02142, USA. Electronic address: devyn@sigilon.com.
  • Culme-Seymour EJ; Gene Therapy, Rare Diseases Unit, R&D, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
  • Mason C; Advanced Centre for Biochemical Engineering, University College London, Bernard Katz building, London, WC1E 6BT, UK; AVROBIO, One Kendall Square, Bldg 300, #201, Cambridge, MA 02139, USA.
Cell Stem Cell ; 22(5): 623-626, 2018 05 03.
Article in En | MEDLINE | ID: mdl-29656942
Cell and gene therapies hold the promise of providing significant and durable health gains to patients in many disease states and have recently elicited significant investor and partner interest. We cover the current state of industry partnerships and investments, highlight what makes a partnership advantageous, and discuss implications for stem cell therapies.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stem Cells / Genetic Therapy / Cell- and Tissue-Based Therapy Limits: Animals / Humans Language: En Journal: Cell Stem Cell Year: 2018 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stem Cells / Genetic Therapy / Cell- and Tissue-Based Therapy Limits: Animals / Humans Language: En Journal: Cell Stem Cell Year: 2018 Document type: Article Country of publication: United States